Commercial low-citrate anticoagulation haemofiltration in high risk patients with frequent filter clotting

Anaesthesia and Intensive Care

Volumn 33, Issue 5, 2005, Pages 601-608

  Naka, T ^a   Egi, M ^a   Bellomo, R ^a,e   Cole, L ^b   French, C ^c   Botha, J ^d   Wan, L ^a   Fealy, N ^a   Baldwin, I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NEPEAN HOSPITAL   (Australia)

^c WESTERN HOSPITAL   (Australia)

^d PENINSULA HEALTH   (Australia)

^e AUSTIN HOSPITAL   (Australia)

Author keywords

Acute renal failure; Haemofiltration: citrate; Intensive care; Ionized calcium

Indexed keywords

CALCIUM; CALCIUM ION; CITRIC ACID; HEPARIN; MAGNESIUM; MAGNESIUM ION;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANION GAP; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD FILTER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOFILTRATION; HIGH RISK PATIENT; HUMAN; HYPOCALCEMIA; MAGNESIUM BLOOD LEVEL; MALE; PATIENT SELECTION; PROSPECTIVE STUDY; SAFETY; SEPSIS; SHOCK;

EID: 27544440480     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0503300509     Document Type: Article

References (27)

1. Ronco C. Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol 1993; 40:187-198.
2. Ronco C, Bellomo R. Continuous renal replacement therapy: evolution in technology and current nomenclature. Kidney Int Suppl 1998; 66:s160-s164.
3. Bellomo R, Boyce N. Continuous venovenous hemodiafiltration compared with conventional dialysis in critically ill patients with acute renal failure. ASAIO J 1993; 39:M794-797.
4. Ward DM, Mehta RL. Extracorporeal management of acute renal failure patients at high risk of bleeding. Kidney Int 1993; Suppl 41: s237-s244.
5. Van de Wetering J, Westendorp RGJ, Vander Hoeven JG et al. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7:145-150.
6. Swartz RD. Hemorrhage during high-risk hemodialysis using controlled heparinization. Nephron 1981; 28:65-69.
7. Kaplan AA, Petrillo R. Regional heparinization for continuous arterio-venous hemofiltration. ASAIO Trans 1987; 33:312-315.
8. Sagedal S, Hartmann A. Low molecular weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous renal replacement therapies. Eur J Med Res 2004; 9:125-130.
9. Hory B, Cachoux A, Toulemonde F. Continuous arteriovenous hemofiltration with low-molecular-weight heparin. Nephron 1985; 41:125.
10. Jeffrey RF, Khan AA, Douglas JT, Will EJ, Davison AM. Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. Artif Organs 1993; 17:717-720.
11. Matsuo T, Kario K, Nakao K, Yamada T, Matsuo M. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis 1993; 23:135-141.
12. Akizawa T, Koshikawa S, Ota K, et al. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron1993; 64:376-381.
13. Ohtake Y, Hirasawa H, Sugai T et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 1991; 93:215-217.
14. Ponikvar R, Kandus A, Buturovic J, Kveder R. Use of prostacyclin as the only anticoagulant during continuous venovenous hemofiltration. Contrib Nephrol 1991; 93:218-220.
15. Langenecker SA, Felfernig M, Werba A et al. Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 1994: 22:1774-1781.
16. Ramesh Prasad GV, Palevsky PM, Burr R et al. Factors affecting system clotting in continuous renal replacement therapy: results of a randomized, controlled trial. Clin Nephrol 2000; 53:55-60.
17. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000; 26:1652-1657.
18. Paganini EP. Slow continuous hemofiltration and slow continuous ultrafiltration. ASAIO Trans 1988; 34:63-66.
19. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous venovenous hemofiltration without anticoagulation. ASAIO J 2004; 50:76-80.
20. Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38:976-981.
21. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55:1991-1997.
22. Kutsogiannis DJ, Mayers I, Chin WDN, Gibney RTN. Regional citrate anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2000; 35:802-811.
23. Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001; 60:370-374.
24. Thoenen M, Schmid ER, Binswanger U et al. Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients. Wien Klin Wochenschr 2002; 114:108-114.
25. Gabutti L, Marone C, Colucci G, Duchini F, Schonholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002; 28: 1419-1425.
26. Dorval M, Madore, F, Courteau S, Leblanc M. A novel citrate anticoagulation regimen for continuous venovenous hemodiafiltration. Intensive Care Med 2003; 29:1186-1189.
27. Tobe SW, Aujla P, Walele AA et al. A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care 2003; 18:121-129.